医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Significant Study of Cluster Dextrin® Now Available from Glico

2014年09月15日 PM12:03
このエントリーをはてなブックマークに追加


 

OSAKA, Japan

In 2013, Glico conducted in vivo human clinical trials with Cluster Dextrin® (Highly Branched Cyclic Dextrin / HBCD). The attendant theses were reviewed, and consequently accepted for publication in the journal Bioscience, Biotechnology and Biochemistry , and are now available to readers.

The studies showed that during a cycling exercise, 24 practiced adult males experienced significantly less exhaustion after being administered 15 grams of Cluster Dextrin® than a similar group given the same amount of maltodextrin. When interviewed they described more energetic performance at both 30 and 60 minute intervals after taking Cluster Dextrin®. Additionally, blood was drawn after 30 minutes and examined for blood sugar levels, which tended to be higher in the Cluster Dextrin® group. This suggests that it offers a pronounced benefit in promoting endurance and reducing fatigue during exercise.

Cluster Dextrin® was developed by Ezaki Glico Co., Ltd. and is distributed by Glico Nutrition Co., Ltd. It offers the optimal benefit a carbohydrate-based supplement can provide in the performance of vigorous exercise.

As an energy source in sports drinks, Cluster Dextrin® has low osmotic pressure, and empties swiftly from stomach to small intestine. There it quickly breaks down to enter the bloodstream, thereby sustaining a high blood sugar level. This metabolic regime shows Cluster Dextrin® to be the most suitable supplement yet developed for drinks used in the performance of high-endurance sports.

Representatives of Glico will be on hand at Supply Side West this October (Booth 18101) to answer questions about this study.

Glico Nutrition Co., Ltd.
6-5, Utajima 4-chome, Nishi Yodogawa-ku
Osaka, 555-8502, Japan
http://www.glico.co.jp/en/material/cluster_dextrin/
g-material@glico.co.jp

CONTACT

For Glico Nutrition Co., Ltd.
Robert Price, 551-574-9398
rprice@mitsubishiingredients.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • BioVectra与Keryx Biopharmaceuticals签署枸橼酸铁扩产协议
  • Eternity Healthcare Inc. Enters into Share Exchange Agreement with Guizho Tongren Healthy China Biotechnology Co. Ltd.
  • Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn’s disease
  • Chi-Med Initiates Fruquintinib U.S. Clinical Trials
  • Orthocell Granted European Tendon Regeneration Patent